The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
The company's clinical services revenues were down 34 percent year over year while product revenues ticked up 7 percent.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
The firm said clinical services revenues fell during the quarter due to reduced insurance reimbursement payments and mix of testing in the prior year.
After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
The firm said the decline in Q4 revenues was due to an account loss as well as lower insurance reimbursement and shifts away from high-value genetic testing.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.